Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Recombinant interferon (IFN) may be useful in the treatment of HIV. However, the high doses
of IFN necessary to keep HIV under control limit its use due to toxic side effects. The
purpose of this study is to test the safety and tolerability of weekly recombinant pegylated
interferon (PEG-IFN) alfa-2a in HIV infected people who are currently on antiretroviral
therapy (ART) interruption or who have not started taking anti-HIV drugs.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)